Mr. D S Brar has been a director of Wockhardt "since April 2012. He is a B.E. (Electrical) from Thapar Institute of Engineering & Technology, Patiala, and holds a master’s degree in Management (Gold Medallist) from Faculty of Management Studies, University of Delhi. Mr. Brar has been associated with the pharmaceutical industry for over three decades and his major stint was at Ranbaxy Laboratories, where he rose to become the CEO & Managing Director. Mr. Brar was a Member of the Prime Minister’s Task Force on pharmaceuticals and knowledge-based industries. Mr. Brar also served as a director of Reserve Bank of India, member on the Board of National Institute of Pharmaceutical Education & Research, and member of the Board of Governors of Indian Institute of Management, Lucknow. He is currently member of the Consultative Group on Exports of Pharmaceutical Products under the chairmanship of the Hon’ble Minister of Commerce, Industry & Textiles, Government of India." 
"Mr. Brar also promoted Inogent Labs – an early development/scale up company (now a wholly owned subsidiary of GVK Biosciences) and Davix Management Services – Pharmaceuticals focused Consulting/Advisory Services Company. Mr. Brar is the Chairman of Mphasis Limited and holds Board positions in various Indian and International companies like Maruti Suzuki India Limited, Wockhardt Limited, Gland Pharma Limited and Mountain Trail Foods (India) Pvt. Ltd. He is also Special Advisor to the Board of Directors of Adamas Pharmaceuticals Inc. and a member of the Advisory Board of the USA-India Chamber of Commerce (USAIC). From 2000–2007, Mr. Brar served as a Director of the Reserve Bank of India (RBI) and was also a Member of the Inspection and Audit Sub-Committee of the Central Board of Directors of the RBI. Mr. Brar also served as a Senior Advisor to Kohlberg Kravis Roberts (KKR) from 2011–2015."
"Brar, who worked with Ranbaxy from 1977 to 2004, played a pivotal role in making it India's largest drug maker with an extensive international footprint. He was closely associated with Parvinder Singh, the late chairman and managing director of the company that Sun Pharmaceuticals is taking over from Japan's Daiichi Sankyo in a record $4-billion deal." 
- Former chairman of GVK Bio